BRIEF-Achillion announces initiation of patient dosing by Janssen in phase 2B study
November 30, 2016 at 06:14 AM EST
* Achillion announces initiation of patient dosing by Janssen in a global, short treatment-duration phase 2B study of JNJ-4178 in chronic HCV
